원문정보
초록
영어
Sodium salicylate, a main metabolite of aspirin, has been shown to protect neurons. Animals injected with 6-hydroxydopamine (6-OHDA), a hydroxylated analogue of dopamine, are well-accepted model revealing nigral degeneration and have served as an animal model of
Parkinson’s disease. In this study, 6-OHDA model was used to test the neuroprotective effects of sodium salicylate in relation to suppression of microglial activation. 6-OHDA induced microglial activation and a significant extent of microglial activation remained at least up to six weeks following a single injection of 6-OHDA into the medial forebrain bundle. However, the response to 6-OHDA was significantly attenuated by sodium salicylate administration. In addition, the survival rate of substantia nigra dopaminergic neurons was better when sodium salicylate treatment was initiated after 6-OHDA lesion than when sodium salicylate was administered prior to the 6-OHDA lesion. These findings suggest that sodium salicylate can act as a negative regulator of
the inflammatory response in dopaminergic system.